Recursion Pharmaceuticals, Inc. - Class A Common Stock - fluxo de caixa trimestral (NASDAQ:RXRX)

Financials

Fluxo de caixa operacional -115.43 M-131.96 M-76.42 M-117.36 M-46.07 M-81.1 M -320.95 M Fluxo de caixa de investimento 275.46 M-7.27 M-5.81 M-2.55 M-1.24 M-338 K -9.94 M Fluxo de caixa de financiamento 10.64 M40.53 M97.66 M251.34 M132.01 M-3.47 M 477.54 M Fluxo de caixa livre -115.43 M-131.96 M-79.57 M-117.6 M-47.32 M-81.44 M -325.93 M

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals is a clinical-stage biotechnology company that focuses on mapping and decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering. The company is based in Salt Lake City, Utah. It was founded by Chris Gibson, Dean Li and Blake Borgeson.

RXRX

Financials

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Notícias

Two Months. $10 Million. A Sputnik Moment for AI.

Ação da Recursion Pharmaceuticals atinge mínima de 52 semanas a US$ 2,79

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Recursion no 1º tri de 2026: pipeline de IA avança apesar de desafios de receita

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine (TEM)

RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

Slides do 1º tri de 2026 da Recursion: pipeline avança apesar da receita abaixo do esperado

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates

AI Revolutionizing Biopharma: Faster, Better, Cheaper (NYSEARCA:XLV)

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know